Delivery Order SPE2DB20D1100-SPE2DB25FE5Q6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,322.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at the awardee's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as...
- The Defense Logistics Agency awarded a delivery order valued at $15,339.52 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 9, 2025, under a firm fixed-price contract with a ceiling value of $27,169.72. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,906.25 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an ultimate completion date of August 18, 2025. This firm fixed-price contract, awarded without a set-aside designation on August 15, 2025, represents a competitively awarded procurement supporting the federal medical supply chain. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,847.74 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement requirements. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $6,223.32. This non-set-aside delivery order is scheduled for completion by September 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. The award represents a discrete purchase order leveraging...
- The Defense Logistics Agency awarded a $3,111.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This non-competitive, non-set-aside delivery order represents a discrete purchase under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The place of performance is listed as Conshohocken, Pennsylvania, which serves as...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,197.01 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count unit of use packaging) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical procurement supporting federal medical supply needs. The contract is performed at AmerisourceBergen's corporate...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE5Q6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 9, 2025, with a ceiling value of $8,602.78 and a firm fixed-price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 10, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, leverages this prime contract vehicle to supply a broad spectrum of pharmaceutical products and medical supplies to support military and federal healthcare systems worldwide. The company's federal procurement portfolio demonstrates extensive capability in delivering medications across multiple therapeutic domains, and DLA is planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional awards, positioning AmerisourceBergen among the key vendors supporting the Defense Health Agency and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 9/9/25 |